# US 2003/0232976 A1 · Streptococcus antigens

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0232976 A1
- Document ID: US20030232976A1
- Status: Published application
- Kind: A1
- Application number: 10/324,143
- Filed: 2002-12-20
- Published: 2003-12-18
- Earliest claimed: 2001-12-20
- Assignees: ID Biomedical Corporation
- Inventors: Josee Hamel; Nathalie Charland; Bernard R. Brodeur; Denis Martin; Normand Blais; Catherine Ouellet; Steve Labbe
- Web page: https://patentgrep.com/patent/US20030232976A1

## CPC

- C07K 14/3156: {from Streptococcus pneumoniae (Pneumococcus) (Streptokinase C07K14/3153)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- C07K 2319/00: Fusion polypeptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to polypeptides of Streptococcus pneumoniae which may be used for prophylaxis, diagnostic and/or therapy purposes.

## Claims

### Claim 1

An isolated polynucleotide comprising a polynucleotide chosen from;
(a) a polynucleotide encoding a polypeptide having at least 70% identity to a second polypeptide chosen from: SEQ ID NO: 1, 2, 3, 90 to 115, 141 to 148 or fragments, analogs or derivatives thereof;
(b) a polynucleotide encoding a polypeptide having at least 95% identity to a second polypeptide chosen from: SEQ ID NO: 1, 2, 3, 90 to 115, 141 to 148 or fragments, analogs or derivatives thereof;
(c) a polynucleotide encoding a polypeptide having an amino sequence chosen from SEQ ID NO: 1, 2, 3, 90 to 115, 141 to 148 or fragments, analogs or derivatives thereof;
(d) a polynucleotide encoding a polypeptide capable of raising antibodies having binding specificity for a polypeptide having a sequence chosen from: SEQ ID NO: 1, 2, 3, 90 to 115, 141 to 148 or fragments, analogs or derivatives thereof;
(e) a polynucleotide encoding an epitope bearing portion of a polypeptide chosen from SEQ ID NO: 1, 2, 3, 90 to 115, 141 to 148 or fragments, analogs or derivatives thereof;
(f) a polynucleotide comprising a sequence chosen from SEQ ID NOS: 4, 5 or 6 or fragments or analogs thereof; and
(g) a polynycleotide complementary to a polynucleotide in (a), (b), (c), (d), (e) or (f).

### Claim 2

An isolated polynucleotide comprising a polynucleotide chosen from;
(a) a polynucleotide encoding a polypeptide having at least 70% identity to a second polypeptide chosen from: SEQ ID 1, 2, 3, 90 to 115 or 141 to 148;
(b) a polynucleotide encoding a polypeptide having at least 95% identity to a second polypeptide chosen from: SEQ ID 1, 2, 3, 90 to 115 or 141 to 148;
(c) a polynucleotide encoding a polypeptide having an amino sequence chosen from SEQ ID 1, 2, 3, 90 to 115 or 141 to 148;
(d) a polynucleotide encoding a polypeptide capable of raising antibodies having binding specificity for a polypeptide having a sequence chosen from: SEQ ID 1, 2, 3, 90 to 115 or 141 to 148;
(e) a polynucleotide encoding an epitope bearing portion of a polypeptide chosen from SEQ ID 1, 2, 3, 90 to 115 or 141 to 148;
(f) a polynucleotide comprising a sequence chosen from SEQ ID NOS: 4, 5 or 6; and
(g) a polynycleotide complementary to a polynucleotide in (a), (b), (c), (d), (e) or (f).

### Claim 3 (depends on 1, 2)

The polynucleotide of anyone of claims 1 or 2, wherein said polynucleotide is DNA.

### Claim 4 (depends on 1, 2)

The polynucleotide of anyone of claims 1 or 2, wherein said polynucleotide is RNA.

### Claim 5 (depends on 1)

The polynucleotide of claim 1 that hybridizes under stringent conditions to either
(a) a DNA sequence encoding a polypeptide or
(b) the complement of a DNA sequence encoding a polypeptide; wherein said polypeptide comprises a sequence chosen from SEQ ID NOS: 1, 2, 3, 90 to 115, 141 to 148 or fragments or analogs thereof.

### Claim 6 (depends on 2)

The polynucleotide of claim 2 that hybridizes under stringent conditions to either
(a) a DNA sequence encoding a polypeptide or
(b) the complement of a DNA sequence encoding a polypeptide; wherein said polypeptide comprises a sequence chosen from SEQ ID NOS: 1, 2, 3, 90 to 115 or 141 to 148.

### Claim 7 (depends on 1)

The polynucleotide of claim 1 that hybridizes under stringent conditions to either
(a) a DNA sequence encoding a polypeptide or
(b) the complement of a DNA sequence encoding a polypeptide; wherein said polypeptide comprises at least 10 contiguous amino acid residues from a polypeptide comprising a sequence chosen from SEQ ID NOS: 1, 2, 3, 90 to 115, 141 to 148 or fragments or analogs thereof.

### Claim 8 (depends on 2)

The polynucleotide of claim 2 that hybridizes under stringent conditions to either
(a) a DNA sequence encoding a polypeptide or
(b) the complement of a DNA sequence encoding a polypeptide; wherein said polypeptide comprises at least 10 contiguous amino acid residues from a polypeptide comprising a sequence chosen from SEQ ID NOS: 1, 2, 3, 90 to 115 or 141 to 148.

### Claim 9

An isolated polynucleotide having a sequence comprising a sequence chosen from SEQ ID NOs: 4, 5, 6 or fragments or analogs thereof.

### Claim 10

An isolated polynucleotide having a sequence comprising a sequence chosen from SEQ ID NOs: 4, 5 or 6.

### Claim 11 (depends on 1)

A vector comprising the polynucleotide of claim 1, wherein said DNA is operably linked to an expression control region.

### Claim 12 (depends on 2)

A vector comprising the polynucleotide of claim 2, wherein said DNA is operably linked to an expression control region.

### Claim 13 (depends on 11)

A host cell transfected with the vector of claim 11.

### Claim 14 (depends on 12)

A host cell transfected with the vector of claim 12.

### Claim 15 (depends on 13)

A process for producing a polypeptide comprising culturing a host cell according to claim 13 under conditions suitable for expression of said polypeptide.

### Claim 16 (depends on 14)

A process for producing a polypeptide comprising culturing a host cell according to claim 14 under conditions suitable for expression of said polypeptide.

### Claim 17

An isolated polypeptide comprising a polypeptide chosen from:
(a) a polypeptide having at least 70% identity to a second polypeptide having an amino acid sequence chosen from: SEQ ID NO: 1, 2, 3, 90 to 115, 141 to 148 or fragments, analogs or derivatives thereof;
(b) a polypeptide having at least 95% identity to a second polypeptide having an amino acid sequence chosen from: SEQ ID NO: 1, 2, 3, 90 to 115, 141 to 148 or fragments, analogs or derivatives thereof;
(c) a polypeptide having an amino acid sequence chosen from SEQ ID NO: 1, 2, 3, 90 to 115, 141 to 148 or fragments, analogs or derivatives thereof;
(d) a polypeptide capable of raising antibodies having binding specificity for a second polypeptide having a sequence chosen from SEQ ID NO: 1, 2, 3, 90 to 115, 141 to 148 or fragments, analogs or derivatives thereof;
(e) an epitope bearing portion of a polypeptide having an amino acid sequence chosen from: SEQ ID NO: 1, 2, 3, 90 to 115, 141 to 148 or fragments, analogs or derivatives thereof;
(f) the polypeptide of (a), (b), (c), (d) or (e), wherein the N-terminal Met residue is deleted; or
(g) the polypeptide of (a), (b), (c), (d), (e), or (f) wherein the secretory amino acid sequence is deleted.

### Claim 18

an isolated polypeptide comprising a member chosen from:
(a) a polypeptide having at least 70% identity to a second polypeptide having an amino acid sequence chosen from: SEQ ID NO: 1, 2, 3, 90 to 115 or 141 to 148;
(b) a polypeptide having at least 95% identity to a second polypeptide having an amino acid sequence chosen from: SEQ ID NO: 1, 2, 3, 90 to 115 or 141 to 148;
(c) a polypeptide having an amino acid sequence chosen from SEQ ID NO: 1, 2, 3, 90 to 115 or 141 to 148;
(d) a polypeptide capable of raising antibodies having binding specificity for a second polypeptide having a sequence chosen from SEQ ID NO: 1, 2, 3, 90 to 115 or 141 to 148;
(e) an epitope bearing portion of a polypeptide having an amino acid sequence chosen from: SEQ ID NO: 1, 2, 3, 90 to 115 or 141 to 148;
(f) the polypeptide of (a), (b), (c), (d) or (e) wherein the N-terminal Met residue is deleted; or
(g) the polypeptide of (a), (b), (c), (d), (e) or (f) wherein the secretory amino acid sequence is deleted.

### Claim 19

A chimeric polypeptide comprising two or more polypeptides chosen from SEQ ID NO: 1, 2, 3, 90 to 115 or 141 to 148 or fragments, analogs or derivatives thereof;
provided that the polypeptides are linked as to form a chimeric polypeptide.

### Claim 20

A chimeric polypeptide comprising two or more polypeptides chosen from SEQ ID NO: 1, 2, 3, 90 to 115 or 141 to 148; provided that the polypeptides are linked as to form a chimeric polypeptide.

### Claim 21 (depends on 13, 14)

A pharmaceutical composition comprising a polypeptide according to any one of claims 13 to 14 and a pharmaceutically acceptable carrier, diluent, adjuvant or liposome.

### Claim 22 (depends on 21)

A method for therapeutic or prophylactic treatment of meningitis, otitis media, bacteremia or pneumonia infection in an individual susceptible to meningitis, otitis media, bacteremia or pneumonia infection comprising administering to said individual a therapeutic or prophylactic amount of a composition according to claim 21.

### Claim 23 (depends on 21)

A method for therapeutic or prophylactic treatment of streptococcal bacterial infection in an individual susceptible to streptococcal infection comprising administering to said individual a therapeutic or prophylactic amount of a composition according to claim 21.

### Claim 24 (depends on 22)

A method according to claim 22, wherein said individual is a mammal.

### Claim 25 (depends on 23)

A method according to claim 23, wherein said individual is a mammal.

### Claim 26 (depends on 22)

A method according to claim 22, wherein said individual is a human.

### Claim 27 (depends on 23)

A method according to claim 23, wherein said individual is a human.

### Claim 28 (depends on 22)

A method according to claim 22, wherein said bacterial infection is S.pneumoniae, group A streptococcus (pyogenes), group B streptococcus (GBS or agalactiae), dysgalactiae, uberis, nocardia or Staphylococcus aureus.

### Claim 29 (depends on 22)

A method according to claim 22, wherein said bacterial infection is S.pneumoniae.

### Claim 30 (depends on 21)

Use of the pharmaceutical composition according to claim 21 for the prophylactic or therapeutic treatment of Streptococcal infection in an animal susceptible to or infected with streptococcal infection comprising administering to said animal a prophylactic or therapeutic amount of the composition.

### Claim 31 (depends on 17, 18, 19, 20)

A kit comprising a polypeptide according to anyone of claims 17 to 20 for detection or diagnosis of streptococcus infection.
